ICON selected by Genomics England to support the largest genome sequencing project of its kind for cancer and rare diseases
09 Fevereiro 2016 - 8:00AM
Business Wire
ICON selected as Data Management Partner for
the 100,000 Genomes Project
ICON plc, (NASDAQ: ICLR) a global provider of drug
development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced that
it has been selected by Genomics England as data management partner
for the 100,000 Genomes Project.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160209005247/en/
A ground-breaking project announced by the British Prime
Minister David Cameron in 2012, the 100,000 Genomes Project is
sequencing 100,000 whole genomes from 70,000 National Health
Service (NHS) cancer and rare disease patients and their families.
It aims to demonstrate a new genomic medicine service for the NHS
to support better diagnosis and more personalised treatments for
patients. De-identified data from the 100,000 Genomes Project will
also be made available to approved researchers from industry to
help accelerate the development of new treatments and diagnostic
tests that are targeted at the genetic characteristics of
individual patients.
As Genomics England’s data management partner, ICON will use its
powerful data management capabilities, and understanding of the
growing role genomics data will have in clinical trials, to
validate clinical data from the 70,000 participating patients and
their families. This work will take place within the secure
Genomics England data environment.
“We are very proud that our genomics knowledge and our
capabilities in securely managing large clinical and real world
datasets have been chosen by Genomics England for such an important
and transformative project,” commented Professor Brendan Buckley,
ICON’s Chief Medical Officer. “Our partnership with Genomics
England demonstrates our commitment to partnering with industry and
government organisations in new and innovative ways to improve
patient care by accelerating the development of targeted and
personalised medicines that tackle complex diseases. Genomics
England’s selection of ICON also reaffirms ICON as a trusted
partner to government organisations as well as the world’s top
pharma, biotech and medical device companies.”
James Peach, Managing Director for the 100,000 Genomes Project
Main Programme at Genomics England said: “We are delighted to be
partnering with ICON. Their renowned expertise in data management
will be fundamental in driving scientific research and accelerating
the return of results for NHS patients.”
About ICON plc
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. ICON has headquarters in Dublin Ireland, and employs over
700 staff in the UK from offices in London, Marlow, Eastleigh,
Abingdon and Edinburgh. Globally, ICON operates from 89 locations
in 38 countries and has approximately 11,900 employees. Further
information is available at www.iconplc.com
About Genomics England
Genomics England is a company owned by the Department of Health
and was set up to deliver the 100,000 Genomes Project. This
flagship project will sequence 100,000 whole genomes from NHS
patients and their families by 2017. Genomics England has four main
aims:
- To bring benefit to patients
- To create an ethical and transparent
programme based on consent
- To enable new scientific discovery and
medical insights
- To kick-start the development of a UK
genomics industry
The project is focusing on patients with rare diseases and their
families, as well as patients with common cancers. More information
is at www.genomicsengland.co.uk
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160209005247/en/
ICON Media ContactPippa ChesterWeber Shandwick+44 (0) 207
067 0571PChester@webershandwick.comorGenomics England Media
ContactKatrina Nevin-RidleyDirector of CommunicationsGenomics
England+44-(0)207 882
6493katrina.nevin-ridley@genomicsengland.co.uk
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024